Comparative Pharmacology
Head-to-head clinical analysis: CLARINEX D 24 HOUR versus LIVOSTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARINEX D 24 HOUR versus LIVOSTIN.
CLARINEX D 24 HOUR vs LIVOSTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desloratadine is a long-acting tricyclic histamine antagonist with selective peripheral H1-receptor antagonist activity. Loratadine is a long-acting antihistamine that selectively antagonizes peripheral H1-receptors.
Levocabastine is a selective histamine H1-receptor antagonist, inhibiting histamine release from mast cells and basophils.
1 tablet (5 mg desloratadine/120 mg pseudoephedrine) orally once daily
1 drop (0.05% ophthalmic solution) in affected eye twice daily, up to 4 times daily if needed.
None Documented
None Documented
Desloratadine: terminal t1/2 27 hours (range 20-50h) supporting once-daily dosing. Pseudoephedrine: t1/2 5-8 hours (up to 16h in alkaline urine).
Terminal elimination half-life in adults: 35-40 hours; clinical context: supports once-daily dosing, with steady-state reached after approximately 7 days
Desloratadine: ~87% excreted as metabolites (41% urine, 43% feces), <2% unchanged. Pseudoephedrine: ~70-90% excreted unchanged in urine.
Renal excretion as unchanged drug and metabolites: ~70% (48% unchanged, 9% as levocabastine glucuronide, 13% as other metabolites); fecal excretion: ~20%
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine